
Pharmaceutical Executive
FDA takes the opportunity to remind industry what reminder ads are, as promotional material for Shire's Fosrenol is deemed in violation of advertising rules

Pharmaceutical Executive
FDA takes the opportunity to remind industry what reminder ads are, as promotional material for Shire's Fosrenol is deemed in violation of advertising rules

Pharmaceutical Executive
Marketers and sales reps feel the brunt of faltering Procrit sales as J&J consolidates its biologics divisions.

Pharmaceutical Executive
Consumer advertising might be taking a hit in the media and Congress, but pharma was all smiles at this year's PhAME Awards as the best DTC campaigns took the spotlight

Pharmaceutical Executive
Technology isn't the magic bullet, but it can help you hit your target

Pharmaceutical Executive
The tech-savvy creative team at Concentric Rx has its sales force mixing work and play

Pharmaceutical Executive
Thanks to Dr. Google and Nurse Yahoo, pharma consumers know better than ever how to get exactly what they want

Pharmaceutical Executive
Promotional spending is down as companies rationalize and optimize budgets. But in contrast to big changes on the sales side, marketers are still trying to make the old model work

Pharmaceutical Executive
As companies make headway with Web promotions, their marketers express concerns about how best to benchmark online efforts.

Pharmaceutical Executive
Blog entries about branded drugs-both positive and negative-are turning up in online keyword searches. Should pharma be worried?

Pharmaceutical Executive
GSK, Pfizer, and Merck have jumped on the cell-phone marketing bandwagon, but most of pharma is still tiptoeing around the technology. A new report details how pharma can get consumers to text for health info.

Pharmaceutical Executive
New study ranks the top RX product sites and looks at the consumers who view them

Pharmaceutical Executive
Talk to MDs in their language and build a better brand

Pharmaceutical Executive
What Big Pharma needs to learn-and value-about this rapidly growing US demographic

Pharmaceutical Executive
A new study looks at the movement of thought leaders and medical science liaisons from primarily marketing to other areas of the pharma company. Though the shift might be minor (7 percent since 2002), it might be a sign of things to come.

Pharmaceutical Executive
Now that Apple has opened its iPhone to third-party software developers, healthcare productivity programs are leading the charge. Here?s a preview of one of the frontrunners.

Pharmaceutical Executive
Pharma is still having a hard time earning the confidence of the key opinion elite, as only 56 percent claim they trust the industry.

Pharmaceutical Executive
A Kaiser Foundation study finds that although most Americans look favorably upon pharmaceuticals, they generally think drugs are too expensive and that most of the cost is blown on advertising.

Pharmaceutical Executive
Industry insiders explain how pharma companies are reorganizing their salesforces in the wake of industry-wide layoffs

Pharmaceutical Executive
New research points to the power of a highly educated sales force, supporting the case for a voluntary educational standard

Pharmaceutical Executive
Why Big Pharma can no longer afford to treat patient adherence programs as an afterthought


Pharmaceutical Executive
IAG Research released its top-10 list of most-recalled new pharma ads of 2007. Many familiar faces top the list, including the Nasonex bee, Abe Lincoln, and Dr. Jarvik, but how many of those faces will still be there next year?

Pharmaceutical Executive
Avenue A|Razorfish's new digital-outlook report indicates that pharma is still floundering online. Though some pharma companies are taking steps to make their online presence known, others are still crawling.

Pharmaceutical Executive
Under pressure from Congress and public scrutiny, Pfizer voluntarily pulled its controversial television campaign for Lipitor featuring Dr. Jarvik.

Pharmaceutical Executive
Pfizer's consumer ads for Lipitor are causing a stir on the blogs and in Congress. Did the company cross the line by using a famous (but unlicensed) doctor to market a drug, or is this a case of a mistaken identity?